Longwall Venture
VC Fund
Harwell, United Kingdom
Longwall Venture is a VC fund in Harwell focused on Biotechnology and Health Care. Longwall Ventures LLP is a venture capital firm specializing in growth capital, early stage, and start-up investments. It targets investing in science including physical science, life science, healthcare, security, media, business software, engineering, and technology companies based in United Kingdom. Longwall Ventures LLP was founded in 2011 and is based in Oxford, United Kingdom.
- Total investments:
- 51
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $98M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Longwall Venture invests in
Stages Longwall Venture invests in
Countries Longwall Venture invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $818k–$5.4M
- Series A
- $2.8M–$16M
- Venture - Series Unknown
- $1.7M–$27M
Investment Focus
Industry
- Biotechnology 14 (27%)
- Health Care 9 (18%)
- Medical Device 7 (14%)
- Medical 5 (10%)
- Manufacturing 5 (10%)
Stage
- Venture - Series Unknown 12 (24%)
- Seed 10 (20%)
- Series A 7 (14%)
- Series B 7 (14%)
- Funding Round 3 (6%)
Country
- United Kingdom 24 (47%)
- Germany 1 (2%)
- Philippines 1 (2%)
- United States 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Denny
Partner
|
Partner | Total investments: 6 | Find email | |
Matthew Frohn
Partner
|
Partner | Total investments: 1 | Find email | |
Rebecca Todd
Investment Director
|
Investment Director | Total investments: 7 | Find email | |
Michael Penington
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.The company's mission is to push the boundaries of complex cell analysis. Using the Lightcast platform, the company is working with major pharmaceutical companies and leading academic institutes to enable them todiscover more. The Lightcast platform allows precise and highly flexible independent control of thousands of droplets. By combining droplets containing different cells, reporters or other reagents we can perform complex workflows without the need to manipulate cells by hand.Lightcast Discovery was founded in 2019 by Cameron Frayling. | $27M / Venture - Series Unknown / Apr 14, 2026 | ||
| OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford. | $160M / Venture - Series Unknown / Feb 24, 2025 | ||
| Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $5.8M / Venture - Series Unknown / Jul 24, 2024 | ||
| Biofidelity developed a revolutionary molecular diagnostic assay that enables the rapid detection of target DNA sequences. Biofidelity’s mission is to improve and extend patients’ lives by enabling early detection of disease and better targeting of treatments with applications spanning oncology, prenatal testing, infectious disease, and organtransplant monitoring.Biofidelity was founded in 2019 and is headquartered of Cambridge, England. | $24M / Venture - Series Unknown / Apr 03, 2024 | ||
| Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries. | $5.3M / Series A / Jan 23, 2024 | ||
| Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.The company's mission is to push the boundaries of complex cell analysis. Using the Lightcast platform, the company is working with major pharmaceutical companies and leading academic institutes to enable them todiscover more. The Lightcast platform allows precise and highly flexible independent control of thousands of droplets. By combining droplets containing different cells, reporters or other reagents we can perform complex workflows without the need to manipulate cells by hand.Lightcast Discovery was founded in 2019 by Cameron Frayling. | $49.8M / Series B / Aug 17, 2023 | ||
| Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries. | $6M / Series B / Apr 19, 2023 | ||
| Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries. | $5.7M / Series A / Apr 19, 2023 | ||
| Caristo Diagnostics is revolutionizing cardiovascular diagnostics and risk prediction with its advanced, AI-based CT imaging analysis tools. | $16.3M / Series A / Apr 17, 2023 | ||
| Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $1.7M / Venture - Series Unknown / Mar 29, 2023 | ||
| See all 51 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Longwall Venture invest in?
Longwall Venture invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Venture - Series Unknown and Seed stage. Most of the 51 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Longwall Venture invest in?
Longwall Venture typically joins rounds of $818k–$5.4M at Seed, $2.8M–$16M at Series A and $1.7M–$27M at Venture - Series Unknown. These are whole funding-round sizes, not Longwall Venture's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Longwall Venture took part in.
How do I contact Longwall Venture?
Public channels for Longwall Venture include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Longwall Venture?
The team at Longwall Venture includes David Denny (Partner), Matthew Frohn (Partner) and Rebecca Todd (Investment Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
